Mavatar Secures SEK 40 Million in Partial Funding Round, Advancing its Leadership in AI-Driven Precision Medicine
Image by Liza Simonsson
Publication date:
October 15, 2024
Mavatar, a Swedish leader in AI-driven precision medicine, today announced the successful completion of a SEK 40 million partial funding round. This strategic investment will accelerate the development of Mavatar's innovative platforms, Mavatar-Insight™ and Mavatar-Precision™, while expanding its operations and global reach.
Mavatar combines over 20 years of research in bioinformatics and artificial intelligence to transform drug discovery and personalized treatment. The Mavatar-Insight™ platform accelerates drug development by analyzing complex genomic data to identify new therapeutic targets and optimize clinical trials. The Mavatar-Precision™ platform creates patient-specific digital replicas—“medical avatars”—that simulate biological processes, enabling highly personalized treatments and improving patient outcomes, particularly in oncology and inflammatory bowel disease (IBD).
"We are thrilled to have secured this funding, which will enable us to scale rapidly and continue advancing our AI platforms," said Johan Juhlin, CEO of Mavatar. "This investment brings us closer to revolutionizing global healthcare with personalized medicine."
The funds will be used to expand operations, advance the Mavatar Insight and Precision ™ platforms, and prepare for a full commercial launch in 2026. Mavatar is also actively seeking additional strategic partners to support its ongoing growth.
"This investment brings us closer to revolutionizing global healthcare with personalized medicine."
Johan Juhlin, CEO at Mavatar